<p>HPGC announced that its wholly-owned subsidiary, Harbin Pharmaceutical Group Biotechnology Co., Ltd., has signed a &#34;Technology Transfer Contract&#34; with Shanghai Bozhi Research and Development Co., Ltd. to purchase the clinical approval for Dapoxetine tablets and to collaborate on subsequent development and market launch matters. The total amount of the contract is expected to be 44.8 million yuan, funded by HPGC's own funds. The transaction does not constitute a related party transaction or a major asset restructuring and does not require submission for shareholder meeting approval</p>

600664

<p>HPGC announced that its wholly-owned subsidiary, HPGC Biotechnology Co., Ltd., has signed a "Technology Transfer Agreement" with Shanghai Bozhi Research and Development Co., Ltd. to purchase the clinical approval for Dapoxetine tablets and to collaborate on subsequent development and market launch matters. The total amount of the contract is expected to be 44.8 million yuan, with funding sourced from HPGC Biotechnology's own funds. The transaction does not constitute a related party transaction or a major asset restructuring and does not require submission for shareholder meeting approval</p>

HPGC: Wholly-owned subsidiary signs "Technology Transfer Contract"